Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Research conducted by scientists and vets at a UK-based animal trust has identified how dogs with a common form of skin cancer could get better treatment.
Zoetis, Merck Animal Health and Biogénesis Bagó have all won Animal Pharm Awards in 2018 – adding to their accolades from previous years.
French firm Ceva Santé Animale is launching MilbeGuard (milbemycin oxime) flavored tablets in the US.
Iowa-based LifEngine Animal Health Laboratories (LEAH) has received a seed investment to support development of canine B cell lymphoma treatment.
Merck Animal Health has signed an exclusive global license agreement with US firm Alopexx Vaccine.
Kindred Biosciences has received positive results from its pilot study of epoCat (KIND-510a), which is a feline recombinant erythropoietin developed for the management of anemia in cats.
Zoetis aims to grow its companion animal revenues at a rate of more than 6% this year – higher than the industry average.
Research from Mars Petcare and the UK's University of Liverpool (UoL) has revealed overweight dogs are more likely to have shorter lives than those at ideal body weights.
Zomedica Pharmaceuticals' diagnostics development work is set to benefit from funding awarded to one of its R&D partners.
Right now, there are more connected 'things' than there are people on this planet. Early last year, research firm Gartner predicted the Internet of Things (IoT) would have at least 8.4 billion connected things in use, rising to more than 20 billion by 2020. Something likely to add to this growth is an emerging smart-sensor movement: The Internet of Animals (IoA). Animal health consultant Dr Tom Overbay explains
The African Small Companion Animal Network (AFSCAN) has launched a pan-Africa infectious disease surveillance program for companion animals.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.